| Literature DB >> 31623664 |
Carole E Aubert1,2, Niklaus Fankhauser3, Pedro Marques-Vidal4, Jérôme Stirnemann5, Drahomir Aujesky6, Andreas Limacher3, Jacques Donzé6,7,8,9.
Abstract
BACKGROUND: Multimorbidity is associated with higher healthcare resource utilization, but we lack data on the association of specific combinations of comorbidities with healthcare resource utilization. We aimed to identify the combinations of comorbidities associated with high healthcare resource utilization among multimorbid medical inpatients.Entities:
Keywords: Chronic diseases; Combinations; Comorbidity; Healthcare utilization; Length of stay; Multimorbidity; Potentially avoidable readmission; Readmission
Mesh:
Year: 2019 PMID: 31623664 PMCID: PMC6798375 DOI: 10.1186/s12913-019-4575-2
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1Study flow-chart. Abbreviations: PAR, potentially avoidable readmission
Baseline characteristics
| Characteristics | Multimorbid population ( |
|---|---|
| Age, years, median (IQR) | 68 (56–78) |
| Men, n (%) | 19,170 (56.6) |
| Length of stay, days, median (IQR) | 8 (4–14) |
| Potentially avoidable readmission, n (%) | 1948 (5.8) |
| Number of admissions in the past year, median (IQR) | 0 (0–2) |
|
| |
| Number of acute and chronic diseases, median (IQR) | 7 (5–10) |
| Number of chronic diseases, median (IQR) | 4 (3–6) |
| Deyo-Charlson Comorbidity Index, median (IQR)a | 2 (1–3) |
| Elixhauser-Van Walraven Comorbidity Index, median (IQR)b | 7 (2–12) |
|
| |
| Chronic heart disease, n (%) | 15,717 (46.4) |
| Chronic kidney disease, n (%) | 5174 (15.3) |
| Solid malignancy, n (%) | 4964 (14,7) |
| Substance-related disorders, n (%) | 4153 (12.3) |
Abbreviations: IQR interquartile range, n number
aA prolonged length of stay was defined as a stay longer than or equal to upper quartile (75%)
aDeyo-Charlson Comorbidity Index ranges from 0 to + 33
bElixhauser-Van Walraven Comorbidity Index ranges from − 19 to + 86
Combinations of comorbidities and 30-day potentially avoidable readmission
| Combinations of comorbidities a | OR (95% CI) | Interaction b | |
|---|---|---|---|
| Acute and unspecified renal failure | Solid malignancy | 2.69 (1.81;3.99) | 0 |
| Pulmonary heart disease | Solid malignancy | 2.48 (1.70;3.63) | 0 |
| Chronic kidney disease | Liver disease | 2.40 (1.60;3.60) | – |
| Chronic kidney disease | Solid malignancy | 2.39 (1.79;3.20) | 0 |
| Solid malignancy | Chronic obstructive pulmonary disease and bronchiectasis | 2.36 (1.75;3.17) | 0 |
| Chronic kidney disease | Chronic obstructive pulmonary disease and bronchiectasis | 2.29 (1.76;2.97) | 0 |
| Chronic kidney disease | Other nutritional, endocrine or metabolic disorders | 2.23 (1.41;3.54) | 0 |
| Chronic kidney disease | Pulmonary heart disease | 2.15 (1.64;2.83) | 0 |
| Esophageal disorders | Solid malignancy | 2.15 (1.39; 3.33) | 0 |
| Liver disease | Solid malignancy | 2.13 (1.41; 3.22) | 0 |
| Chronic kidney disease | Other and ill-defined heart disease | 2.13 (1.45;3.13) | 0 |
| Chronic kidney disease | Other diseases of kidney and ureters | 2.11 (1.41;3.16) | – |
| Chronic kidney disease | Thyroid disorders | 2.09 (1.53;2.85) | 0 |
| Pulmonary heart disease | Chronic obstructive pulmonary disease and bronchiectasis | 2.06 (1.51;2.80) | 0 |
| Chronic kidney disease | Chronic heart disease | 2.02 (1.77;2.30) | 0 |
| Chronic heart disease | Systemic lupus erythematosus and connective tissue disorders | 2.01 (1.26;3.21) | 0 |
| Paralysis | Other nervous system disorders | 1.98 (1.39;2.82) | + |
| Chronic kidney disease | Nephritis, nephrosis, renal sclerosis | 1.95 (1.55;2.47) | 0 |
| Epilepsy; convulsions | Solid malignancy | 1.92 (1.25;2.95) | 0 |
| Chronic heart disease | Other lower respiratory disease | 1.92 (1.18;3.13) | 0 |
Abbreviations: CI confidence interval, OR odds ratio, PAR potentially avoidable readmission
a20 combinations with the highest OR for PAR
b The sign "+"represents a significant more than multiplicative effect of the comorbidities found in the combination on the odds for PAR. A more than multiplicative effect means that the OR of the combination is larger than the ORs of the single comorbidities multiplied together. The sign "-"represents a significant less than multiplicative effect of the comorbidities found in the combination on the odds for PAR. A less than multiplicative effect means that the OR of the combination is smaller than the ORs of the single comorbidities multiplied together. The sign "0"means that there is no significant interaction
Combinations of comorbidities and prolonged length of stay
| Combinations of comorbidities a | OR (95% CI) b | Interaction c | Difference in median LOS (95% CI) d | |
|---|---|---|---|---|
| Miscellaneous mental health disorders | Mood disorders | 11.28 (8.71;14.61) | + | 17.3 (16.5;18.3) |
| Diseases of white blood cells | Hematological malignancy | 10.95 (9.06;13.24) | + | 15.7 (15.1;16.8) |
| Chronic heart disease | Chronic ulcer of skin | 4.83 (3.77;6.17) | + | 7.8 (6.8;8.7) |
| Anxiety disorders | Mood disorders | 4.10 (3.06;5.49) | 0 | 7.6 (6.4;8.8) |
| Chronic heart disease | Diseases of white blood cells | 3.92 (3.01;5.11) | 0 | 8.0 (7.0;9.1) |
| Paralysis | Solid malignancy | 3.37 (2.54;4.47) | 0 | 6.6 (5.5;7.8) |
| Chronic heart disease | Liver disease | 3.36 (2.76;4.08) | + | 6.2 (5.5;7.0) |
| Chronic kidney disease | Chronic ulcer of skin | 3.22 (2.40;4.31) | – | 5.4 (4.2;6.5) |
| Chronic heart disease | Hematological malignancy | 3.21 (2.62;3.92) | 0 | 5.2 (4.3;6.0) |
| Chronic kidney disease | Hematological malignancy | 3.16 (2.42;4.14) | 0 | 4.3 (3.2;5.4) |
| Arthropathy and arthritis | Mood disorders | 3.10 (2.42;9.96) | – | 5.7 (4.8;6.7) |
| Paralysis | Other nervous system disorders | 3.02 (2.40;3.78) | 0 | 5.1 (4.2;6.0) |
| Miscellaneous mental health disorders | Chronic heart disease | 3.01 (2.30;3.93) | 0 | 4.8 (3.8;5.9) |
| Dementia | Mood disorders | 2.95 (2.27;3;82) | – | 5.6 (4.6;6.6) |
| Paralysis | Epilepsy; convulsions | 2.92 (2.28;3.75) | 0 | 5.0 (4.0;6.0) |
| Other nervous system disorders | Mood disorders | 2.89 (2.28;3.66) | 0 | 5.9 (5.0;6.9) |
| Chronic kidney disease | Liver disease | 2.89 (2.19;3.80) | 0 | 4.9 (3.8;6.1) |
| Dementia | Substance-related disorders | 2.83 (2.13;3.75) | 0 | 5.1 (3.9;6.2) |
| Other nervous system disorders | Cerebrovascular disease | 2.79 (2.21;3.54) | 0 | 4.6 (3.7;5.6) |
| Epilepsy; convulsions | Cerebrovascular disease | 2.79 (2.09;3.73) | + | 5.3 (4.2;6.5) |
Abbreviations: CI confidence interval, LOS length of stay, OR odds ratio
a20 combinations with the highest OR for PAR
bA prolonged length of stay was defined as a stay longer than or equal to the upper quartile (75%)
cThe signs "+" and "-"represent a significant more than multiplicative effect and less than multiplicative effect, respectively, of the comorbidities found in the combination on the odds for a prolonged LOS. A more than multiplicative effect means that the OR of the combination is higher than the ORs of the single comorbidities multiplied together. The sign "0"means that there is no significant interaction
dp-value < 0.001 for all. A confidence interval not overlapping the zero line means that the difference in median is significant
Fig. 2Association between the number of chronic diseases and 30-day potentially avoidable readmission. Legend: Odds ratio (box) with 95% confidence interval (lines) for 30-day potentially avoidable readmission. The reference category is the presence of 2 chronic diseases, as we included only patients with multimorbidity. Abbreviations: #, number of chronic diseases; CI, confidence interval; OR, odds ratio
Fig. 3Association between the number of chronic diseases and prolonged length of stay. Legend: Odds ratio (box) with 95% confidence interval (lines) for prolonged length of stay. The reference category is the presence of 2 chronic diseases, as we included only patients with multimorbidity. A prolonged length of stay was defined as a stay longer than or equal to the upper quartile (75%). Abbreviations: #, number of chronic diseases; CI, confidence interval; OR, odds ratio